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   Drug Profile
Depression is a complex and heterogeneous con-
dition with a range of diverse etiologies, which 
include genetic, traumatic, medical, personality 
and social interpersonal factors. In consort, it has 
both a pleomorphic phenomenology and treat-
ment needs, which may reflect such divergence in 
its roots. Unsurprisingly, up to 53% of patients 
suffering from a major depressive episode will 
fail to respond to an adequate trial of treatment 
with a single antidepressant [1]. In the Sequenced 
Treatment Alternatives to Relieve Depression 
(STAR*D) study, outpatients (n = 2,876; baseline 
Hamilton Depression Rating Scale [HAM-D] 
≥14) were treated with citalopram. Remission 
(HAM-D ≤7) was achieved by 27.5% (n = 790) 
of outpatients and required on average 12 weeks 
of treatment [1]. These data suggest that failure of 
antidepressant monotherapies is commonplace. 
Consequently, other psychological, social and 
pharmacological treatment options, which may 
include antidepressant and atypical antipsychotic 
combinations, may need to be considered.
There is no broadly accepted definition of treat-
ment-resistant depression (TRD). A pragmatic 
definition is failure to respond after adequate tri-
als of treatment with two or more anti depressants 
for an adequate time and at an adequate dose 
[2]. Thase proposed staging criteria for TRD, 
where stage 1 was failure on an adequate trial 
of an antidepressant, stage 2 was failure of two 
antidepressants with distinct mechanisms of 
action, stage 3 was stage 2 resistance plus failure 
of a tricyclic antidepressant, stage 4 was stage 3 
resistance plus failure of a monoamine oxidase 
inhibitor and stage 5 was stage 4 resistance plus 
failure of bilateral electroconvulsive therapy [3]. 
This proposed staging model omits many impor-
tant treatment options, particularly combination 
and augmentation therapies; however, the model 
can be adapted to include specific therapies and 
the concept remains useful.
Many pharmacological and nonpharmaco-
logical treatment strategies have been investigated 
for the management of TRD. Pharmacological 
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Antidepressant monotherapy is a first-line treatment for depression; however, not all sufferers 
will adequately respond to treatment. When treating a patient with treatment-resistant 
depression, the clinician needs to consider all factors which may contribute to an inadequate 
response to an antidepressant. These include accuracy of diagnosis and medication adherence, 
as well as the patient’s personality, lifestyle, life events and social circumstances. If it is determined 
that treatment resistance is due to failure of efficacy of antidepressant monotherapy, then an 
augmentation strategy using an atypical antipsychotic may be considered. Treatment using 
olanzapine/fluoxetine combination (OFC) is one of many options. Four randomized, acute-phase 
trials have suggested OFC is useful for reducing Montgomery–Åsberg Depression Rating Scale 
scores after inadequate response to antidepressant monotherapy. OFC has been useful at doses 
of olanzapine/fluoxetine 6/25, 6/50, 12/25 and 12/50 mg/day, with 1/5 mg/day suggested to 
be an ineffective dose. Treatment with OFC has been associated with some side effects, including 
weight gain and the metabolic syndrome, somnolence, dry mouth, increased appetite and 
headache. Treatment decisions therefore need to be made to balance the risks and benefits.
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strategies have included antidepressant dose optimization [4], 
antidepressant combinations [5] and antidepressant augmentation 
strategies [6]. Several psychological therapies have been shown to 
be useful for treating depression and augmenting antidepressant 
response. In a study of adolescents with major depressive disorder 
(MDD) who had not responded to 2-month treatment with a 
selective serotonin reuptake inhibitor (SSRI; n = 334), 12 weeks of 
switching to cognitive–behavioral therapy (CBT) plus a different 
SSRI or venlafaxine was superior to switching to a different SSRI 
or venlafaxine alone for change in Clinical Global Impression 
(CGI) score [7], suggesting that adjunctive psychotherapy may be 
a useful strategy for TRD. There are some data to suggest that 
CBT may be more effective than supportive or family therapies 
for depression [8]. Mindfulness-based cognitive therapy may be 
useful for TRD [9].
A pharmacological strategy for the treatment of TRD is to 
combine a SSRI with an atypical antipsychotic. Olanzapine/
fluoxetine combination (OFC) is one such treatment option. 
Other atypical/antidepressant combinations have also been 
studied, including aripiprazole and quetiapine [10–13,101]. The 
use of OFC is supported by a theoretical rationale for its use and 
clinical evidence of efficacy in TRD. Olanzapine and fluoxetine 
are both well established medications used for the treatment 
of various mental illnesses. The first randomized, controlled 
trial of olanzapine in schizophrenia was published in 1996 [14] 
and trialed in combination with fluoxetine for MDD in 2001 
[15]. Fluoxetine is an older drug with many controlled trials in 
depression conducted in the 1980s [16]. OFC can be administered 
as any combination of the olanzapine and fluoxetine moieties, 
or a single capsule containing the two agents in combination 
in olanzapine/fluoxetine equivalent doses of 3/25, 6/25, 6/50, 
12/25 and 12/50 mg.
Few treatments have been registered by regulatory authorities 
for the treatment of TRD. Vagus nerve stimulation (VNS) is the 
only treatment for TRD currently approved by the US FDA [102]. 
Aripiprazole was recently approved by the FDA and indicated for 
use as an adjunctive treatment to antidepressants for MDD after 
its efficacy was demonstrated in two 6 week, placebo-controlled 
trials of patients with MDD with an inadequate response to prior 
antidepressant therapy [101]. Currently, OFC is only recognized 
as indicated for TRD in Mexico. At this stage, FDA approval for 
the use of OFC has been granted only for the treatment of bipolar 
depression. Other treatment options for TRD include antidepres-
sant combination therapies [5] and augmentation strategies [6], 
which have been reviewed elsewhere. 
Berman et al. randomized patients with a current major depres-
sive episode with inadequate response to one prospective and at least 
one previous antidepressant to 6 weeks of adjunctive aripiprazole 
(n = 184) or adjunctive placebo (n = 178) [12]. Mean change in the 
Montgomery–Åsberg Depression Rating Scale (MADRS) total 
score was -8.8 with adjunctive aripiprazole and -5.8 with adjunctive 
placebo, which was statistically significant (p < 0.001).
McIntyre et al. found significant improvement in HAM-D 
and Hamilton Anxiety Rating Scale (HAM-A) total scores in a 
randomized, placebo-controlled trial of quetiapine as an adjunct 
to an antidepressant (SSRI or serotonin–norepinephrine reuptake 
inhibitor [SNRI]) in patients (n = 58) who had failed to respond to 
6 weeks of antidepressant monotherapy [11]. El-Khalili et al. found 
that adjunctive quetiapine 300 mg/day, but not 150 mg/day, was 
superior to placebo for change in MADRS total score in a 6-week, 
double-blind, randomized trial of MDD (n = 446), in patients 
who had not adequately responded to treatment with a SSRI, 
SNRI, tricyclic antidepressant or bupropion [13]. Martinez et al. 
found that quetiapine plus fluoxetine was superior to fluoxetine 
plus placebo for patients with insomnia in an 8-week trial of 
patients with MDD (n = 114) [10]. Efficacy in MDD of quetia-
pine monotherapy has been shown in two randomized, double-
blind, placebo controlled trials. Quetiapine (50 mg/day, n = 182; 
150 mg/day, n = 178; 300 mg/day, n = 184) was superior to pla-
cebo (n = 184) for reduction in MADRS scores in a 6-week trial 
of acute depression [17]. In a 52-week maintenance trial, the risk 
of depressive relapse was significantly less for quetiapine (n = 391) 
compared with placebo (n = 385) [18].
In a 6-month trial, Lecrubier et al. randomized patients with 
dysthymia and major depression to amisulpride (n = 73), imip-
ramine (n = 73) or placebo (n = 73) and found that amisulpride 
was equivalent to imipramine and superior to placebo for response 
measured using the CGI rating [19]. 
Patients who did not respond to 6 weeks of open-labeled sertra-
line monotherapy were randomly assigned by Dunner et al. to ser-
traline monotherapy (n = 20), sertraline plus ziprasidone 80 mg/
day (n = 22) or sertraline plus ziprasidone 160 mg/day (n = 19) 
for 8 weeks [20]. The mean changes in MADRS scores were -5.98 
with monotherapy, -8.27 with ziprasidone 80 mg/day and -4.45 
with ziprasidone 160 mg/day, with no statistically significant dif-
ference between any of the treatment arms.
Gharabawi et al. trialed adjunctive risperidone (n = 141) or 
adjunctive placebo (n = 133) for 6 weeks in patients who had 
insufficiently responded to 8 weeks of treatment with anti-
depressant monotherapy [21]. The discontinuation rate owing to 
adverse events was 6% in risperidone- and 2% in placebo-treated 
patients. Adjunctive risperidone treatment was associated with 
significant improvement in HAM-D scores from weeks 4 to 6 
when compared with placebo (p < 0.03). Ostroff and Nelson 
reported remission following risperidone augmentation in patients 
with MDD who failed to respond to treatment with fluoxetine 
(n = 5) or paroxetine (n = 3) [22]. 
Chemistry of OFC
The two agents, olanzapine and fluoxetine, are combined to form 
OFC. Olanzapine is a thienobenzodiazepine with the structure 
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]
benzodiazepine and the structure of fluoxetine is (±)-N-methyl-3-
phenyl-3-[(α,α,α,-trifluoro-p-tolyl)oxy]propylamine (Figure 1).
Pharmacokinetics
The pharmacokinetics of OFC appears to be similar to that of 
the individual components, olanzapine and fluoxetine; however, 
fewer data are available for the combination therapy than for the 
components. The potential for a pharmacokinetic interaction 
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between olanzapine and fluoxetine exists 
by inhibition of CYP2D6 by fluox etine. 
Following 8 days of treatment with flu-
oxetine (60 mg/day), Gossen et al. dosed 
healthy, nonsmoking adults (n = 15; age 32 
± 5 years [mean ± standard deviation; SD]) 
with olanzapine (5 mg) and found that 
olanzapine achieved a maximum plasma 
concentration 18% higher compared with 
the same olanzapine dose in the same sub-
jects without fluoxetine pretreatment [23]. 
This interaction has not been demonstrated 
at lower doses of fluoxetine. 
No data are available on OFC in special 
populations; the elderly, renal or hepati-
cally impaired individuals, and the impact 
of gender differences and smoking status 
is unknown. No studies of OFC and CYP2D6 polymorphisms 
have been reported. The reported modest pharmacokinetic 
inter action between olanzapine and fluoxetine is thus of unclear 
clinical significance. 
Olanzapine undergoes extensive Phase I and II metabolism, 
with 10-N-glucoronidation being the prominent metabolic path-
way. Minor metabolic pathways for olanzapine involve CYP2D6 
and CYP1A2. There is little potential for CYP450 inhibition 
by olanzapine within the therapeutic dose range. Following 
oral administration in physically healthy subjects, olanzapine 
(0.5–15 mg) has linear and dose-proportional pharmacokinetics 
with the following parameters (mean ± SD): elimination half-life: 
33.1 ± 10.3 h; apparent volume of distribution: 1148 ± 360 l; 
apparent plasma clearance: 26.1 ± 12.1 l/h. Maximum plasma 
concentration of olanzapine occurs approximately 6 h follow-
ing a single dose. Olanzapine is extensively metabolized in the 
liver to form several nonactive demethylated, hydroxylated and 
glucuronidated metabolites. Olanzapine clearance does not vary 
with CYP2D6 metabolizer status [24]. 
Fluoxetine is a racemic mixture of S- and R-enantiomers, each of 
which has a different pharmacokinetics profile, with R-fluoxetine 
cleared more efficiently than S-fluoxetine. Additionally, fluoxetine 
has a major active metabolite, S- and R-norfluoxetine. Fluoxetine 
has the following pharmacokinetic parameters: volume of dis-
tribution 14–100 l/kg; elimination half-life 1–4 days for fluox-
etine and 7–15 days for norfluoxetine. Fluoxetine has a nonlinear 
pharmacokinetic profile with plasma concentrations increasing 
disproportionately with dose escalation. Fluoxetine is metabolized 
by CYP2C9, CYP2C19, CYP2D6 and CYP3A4 to norfluoxetine, 
and is an inhibitor of CYP2D6 and other P450 enzymes with 
known consequent drug–drug interactions. Glucuronide and 
other nonactive metabolites are also formed [25]. Clearance varies 
with CYP2D6 metabolizer status [26].
Pharmacodynamics
Olanzapine has a high affinity (K
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receptor binding sites [27]. The psychotropic activity of olanzapine 
is thought to be due to antagonism of these dopamine, serotonin, 
α
1
-adrenergic and muscarinic receptors [28].
Fluoxetine inhibits reuptake by the serotonin transporter 
(K
i
 = 5.7 nM/l), and weakly inhibits the norepinephrine 
transporter (K
i
 = 574 nM/l) and the dopamine transporter 
(K
i

















 = 702 nM/l) receptors 
[29]. The psychotropic activity of fluoxetine is due to inhibition 
of presynaptic serotonin reuptake by binding with the serotonin 
reuptake transporter [30]. 
The mechanism of action of OFC in TRD may be due to addi-
tive affects of the mechanisms of action of the two components, 





 receptors may enhance the serotonergic 
efficacy of fluoxetine [3]. Zhang et al. demonstrated significant 
increases in extracellular serotonin, dopamine and norepineph-
rine in the prefrontal cortex of OFC-treated rats [31]. Over a 
4-h period, extracellular serotonin increased 338%, dopamine 
increased 332% and norepinephrine increased 260% compared 
with baseline. At the 4-h time point, the increases in extra cellular 
dopamine and norepinephrine, but not serotonin, were signifi-
cantly greater (p < 0.05) for the OFC-treated rats than for either 
monotherapy. Similar results were obtained for a related study, 
where increases in extracellular dopamine and norepinephrine, 
but not serotonin, compared with either monotherapy were 
observed in the prefrontal cortex of rats when risperidone and 
citalopram were co-administered [32].
Atypical antipsychotics share pharmacological mechanisms, 
which may be significant for their antidepressant effect. Antagonism 
of the 5-HT
2A
 receptor has been suggested to be of particular 
importance [33] and is an important part of the mechanism of action 
of three known effective antidepressants: nefazodone, trazodone 
and mirtazapine. All of the atypical antipsychotics have a greater 
Figure 1. Olanzapine and fluoxetine are combined to form the olanzapine/
fluoxetine combination
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affinity for the 5-HT
2A
 receptor than for the D
2
 receptor. Agonists 
of the 5-HT
1A
 receptor and antagonists of the 5-HT
2A
 receptor 
modulate dopaminergic neurotransmission [33]. The antidepres-
sant activity of quetiapine has been attributed to norepinephrine 
reuptake inhibition and 5-HT
1A
 agonism [34]. These data suggest 
that efficacy of atypical antipsychotics as augmenting agents for 
antidepressants may be a function of intrinsic properties specific 
to individual agent and their interaction with the mechanism of 
the partner antidepressant. The usefulness of individual agents and 
the effectiveness of specific combinations may thus vary.
Clinical studies
Efficacy of olanzapine/fluoxetine combination in 
treatment-resistant depression
Several clinical trials of OFC in TRD have been published. In 
two 8-week, double-blind trials (n = 124 and 125), Rothchild et al. 
found OFC to be superior to placebo and olanzapine monotherapy 
for the treatment of depression with psychotic features in one trial 
[35]. Several studies have shown OFC to be useful for the treatment 
of bipolar depression, both in the acute phase [36,37] and in mainte-
nance [38]. Treatment of bipolar depression with OFC is associated 
with a rapid onset of antidepressant effect [39], improvement of 
health-related quality of life [40], and is not associated with sig-
nificantly increased rates of treatment-emergent mania [41]. In an 
8-week double-blind trial, Zanarini et al. randomized women with 
borderline personality disorder to fluoxetine (n = 14), olanzapine 
(n = 16) and OFC (n = 15) with improvement in depressive and 
impulsive aggression symptoms observed in all treatment arms [42]. 
Clinical trials of OFC in TRD are summarized in Table 1.
Dubé et al. conducted a meta-ana lysis of the two TRD t rials [43]: 
Shelton et al. [44] and Corya et al. [45] (first 8 weeks of double-blind 
treatment included in the meta-ana lysis only). In the meta-ana-
lysis, early onset of action and efficacy of OFC compared with 
olanzapine or fluoxetine monotherapies was confirmed, with 
effects evident from day 7 and maintained for 8 weeks. 
Thase et al. conducted a large efficacy study of OFC in TRD [46]. 
Outpatients with a current depressive episode who had failed to 
respond to at least one 6-week trial of an antidepressant (excluding 
fluoxetine) during the current episode were treated for 8 weeks 
with fluoxetine. Fluoxetine nonresponders began an 8-week, 
double-blind, randomized trial with three treatment arms: OFC 
(n = 200), fluoxetine (n = 206) and olanzapine (n = 199). The 
Table 1. Summary of clinical trials of olanzapine/fluoxetine combination in treatment-resistant depression.
Investigators Participants Treatment arms Study comments Findings Ref.
Corya et al. Nonpsychotic TRD with 
history of failure of an 
SSRI and prospective 
failure of 7 weeks of 
venlafaxine
12-week, double-blind, 
randomized trial of OFC 
(n = 302), olanzapine 
(n = 62), fluoxetine (n = 60) 
or venlafaxine (n = 59)
Five-dose arms of OFC 
(olanzapine 1 mg/day, 
fluoxetine 5 mg/day to 
olanzapine 12 mg/day, 
fluoxetine 50 mg/day)
With low dose OFC excluded 
from the ana lysis, OFC was 
superior to monotherapy arms 
from week 1 to 6 for MADRS 
change from baseline, but 
equivalent to venlafaxine from 
weeks 7 to 12 and to 
fluoxetine at week 12
[45]
Shelton et al. Recurrent TRD without 
psychotic features. 
Prospective failure of 
6 weeks of fluoxetine
8-week, double-blind, 
randomized trial of OFC 
(n = 10), olanzapine (n = 8)  
or fluoxetine (n = 8) 
Participants who 
completed the blinded 
study entered an 8-week 
open-labeled OFC 
extension
MADRS change from baseline 
superior for OFC at weeks 
1–8 versus fluoxetine and 
weeks 1–2, 4–8 versus 
olanzapine 
[15]
Shelton et al. TRD with history of 
failure to an SSRI and 
prospective failure of 
7 weeks of nortriptyline
8-week, double-blind, 
randomized trial of OFC 
(n = 146), olanzapine 
(n = 144), fluoxetine (n = 142) 
or nortriptyline (n = 68)
Asthenia, somnolence, 




and nausea reported 
with OFC treatment
MADRS change from baseline 
superior for OFC at weeks 
2–5 versus fluoxetine, 
weeks 2, 4, 6–7 versus 
olanzapine and weeks 1–4 
versus nortriptyline
[44]
Thase et al. MDD with history of 
antidepressant failure in 
the current episode and 
prospective failure of 
8 weeks of fluoxetine
8-week, double-blind, 
randomized trial of OFC 
(n = 200), olanzapine 
(n = 199) or fluoxetine 
(n = 199)
52 (26%) of  
participants treated  
with OFC discontinued 
before 8 weeks, 
27 (13.5%) owing to  
an adverse event
MADRS change from baseline 
superior for OFC at weeks 1, 
4–8 versus fluoxetine, weeks 
1–8 versus olanzapine
[46]
Corya et al. MDD (n = 560) 76-week, open-labeled 
treatment with OFC
Study included 145 
participants with TRD
Response, remission and 
relapse rates were 53, 44 and 
25%, respectively, for TRD 
patients
[47]
MADRS: Montgomery-Åsberg Depression Rating Scale; MDD: Major depressive disorder; OFC: Olanzapine/fluoxetine combination; SSRI: Selective serotonin reuptake 
inhibitor; TRD: Treatment-resistant depression.
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mean doses were OFC 8.6/48.8 mg/day, fluoxetine 49.5 mg/day 
and olanzapine 8.7 mg/day. Improvements in MADRS scores 
were greater for OFC (-12.7) than fluoxetine (-9.0, p < 0.001) or 
olanzapine (-8.8, p < 0.008). Remission rates were 27% for OFC, 
17% for fluoxetine and 15% for olanzapine.
An 8-week, double-blind, pilot study of TRD was conducted 
with participants who had failed to respond to two different classes 
of antidepressants. After a 6-week fluoxetine open-label lead-in 
phase, participants were randomized to OFC 5–20/20–60 mg/day 
(n = 10), fluoxetine 20–60 mg/day plus placebo (n = 10) and 
olanzapine 5–20 mg/day plus placebo (n = 8). OFC was supe-
rior to fluoxetine or olanzapine for reduction of MADRS score 
(p < 0.05) after 1 week of treatment and the difference remained 
significant at the study end point [15]. A larger, similar study 
was conducted with participants who had failed to respond to a 
SSRI (including fluoxetine). After a 7-week nortriptyline lead-in 
open-labeled phase, participants were randomized to 8 weeks of 
OFC 6–12/25–50 mg/day (n = 146), fluoxetine 25–50 mg/day 
(n = 142), olanzapine 6–12 mg/day (n = 144) or nortriptyline 
25–175 mg/day (n = 68). Improvement in MADRS scores was 
greater with OFC compared with all other treatment arms at sev-
eral early time points. However, there was no significant difference 
between treatment arms at the study end point [44]. 
Corya et al. conducted a study of TRD in depressed subjects 
who had failed to respond to at least 6 weeks of treatment with a 
SSRI [45]. After a 7-week venlafaxine lead-in open-labeled phase, 
participants were randomized to 12 weeks of OFC 1/5 (olanzapine 
1 mg/day, fluoxetine 5 mg/day; n = 59), OFC 6/25 (olanzapine 
6 mg/day, fluoxetine 25 mg/day; n = 63), OFC 6/50 (olanzapine 
6 mg/day, fluoxetine 50 mg/day; n = 63), OFC 12/25 (olanzapine 
12 mg/day, fluoxetine 25 mg/day; n = 60), OFC 12/50 (olanzap-
ine 12 mg/day, fluoxetine 50 mg/day; n = 57), fluoxetine (25 or 
50 mg/day; n = 60), olanzapine (6 or 12 mg/day; n = 144) or ven-
lafaxine (75–375 mg/day; n = 68). The lowest dose of OFC failed 
to differentiate from antidepressant or the olanzapine monotherapy 
treatment arm for change in baseline of MADRS scores. Other 
doses of OFC were superior to all monotherapy treatment arms 
from weeks 1–6 (p < 0.05); however, by study end point, week 12, 
OFC was only superior to olanzapine monotherapy. Of the differ-
ent OFC doses, OFC 1/5 (olanzapine 1 mg/day, fluoxetine 5 mg/
day) appears to be subtherapeutic and OFC 6/25 mg/day (olanzap-
ine 6 mg/day, fluoxetine 25 mg/day) was superior to higher doses 
at weeks 8–12. Corya et al. found OFC 6–18/25–75 mg/day to 
be useful for the treatment of MDD in a 76-week, open-labeled 
study of 560 patients [47]. It is worth noting that the trial of Thase 
et al. was the only study that supports the superiority of OFC over 
fluoxetine monotherapy at the study end point [46].
While there have been several acute-phase studies, there is a 
paucity of data from maintenance studies of OFC in TRD. In an 
open-labeled study, Corya et al. treated participants with MDD 
with OFC for 76 weeks [47]. Participants were grouped as treat-
ment resistant and nontreatment resistant by physician-defined 
diagnosis. Mean MADRS scores were 31.3 at baseline and fell by 
22.3 points at 76 weeks for the non-TRD participants (n = 407), 
and the mean MADRS scores at baseline were 32.6 and fell by 
19.2 points at 76 weeks for the TRD participants (n = 145). 
Response rates were 64.6 and 53.1%, and relapse rates were 12.1 
and 25.0% for non-TRD and TRD participants, respectively. 
The clinical importance of the time of onset of action of OFC 
seen in several trials is unclear. In all TRD studies, OFC treat-
ment arms separated from other treatment arms from week 1 
following 6–8-week antidepressant monotherapy lead-in phases. 
The lead-in phase may have contributed to treatment response. 
In trials of bipolar depression without a lead-in phase, response 
to OFC has been documented from week 1 [39]. 
Tolerability of olanzapine/fluoxetine combination
OFC has a similar qualitative side-effect profile to its combined 
components, olanzapine and fluoxetine, although of potentially 
greater severity and frequency than with monotherapy. Adverse 
effects associated with monotherapy with either of the two com-
ponents also appear to be present in OFC treatment. OFC is 
associated with weight gain similar to olanzapine monotherapy 
and an increased QTc interval similar to fluoxetine. However, 
increased cholesterol with OFC treatment was shown to be sig-
nificantly greater compared with monotherapy with olanzapine or 
fluoxetine [45]. OFC is associated with greater diarrhea and nausea 
[37], and elevated prolactin levels [44] compared with olanzapine 
monotherapy, and greater somnolence and peripheral edema com-
pared with fluo xetine [45]. In a 76-week study, mean weight gain 
for participants treated with OFC was 5.6 kg, which is similar 
to that reported for olanzapine monotherapy [47]. In 8 weeks of 
OFC treatment, participants (n = 500) showed a small increase in 
mean cholesterol (+0.36 mmol/l), QTc prolongations consistent 
with those shown for fluoxetine monotherapy and a mean weight 
gain of 3.28 kg [44]. Treatment with OFC has been associated with 
orthostatic hypotension in some patients, although this is usually 
only during the initial dose-titration period [103]. 
In overdose, OFC may be fatal, although most (possibly all) 
reports are in combination with alcohol or other substances. 
Respiratory depression due to OFC overdose and alcohol has been 
reported [48]. OFC has not been studied in special populations. 
No clinical trial data are available for the use of OFC in people 
under 18 or over 65 years of age, or during pregnancy. 
Expert commentary
When encountering treatment resistance the clinician must first 
consider factors other than choice of medication. First, the diagno-
sis needs to be reconfirmed. Some individuals with TRD later turn 
out to have other diagnoses, including organic pathologies, person-
ality disorder and bipolar disorder. In a study of bipolar disorder 
and schizoaffective disorder (n = 240), a prior diagnosis of depres-
sion was reported by 26.6% of participants [49]. Unrecognized and 
untreated medical or psychiatric comorbidities, persistent stressors, 
personality factors or substance use may also underpin treatment 
resistance and merit specific attention. Secondly, attention needs to 
be paid to medication adherence. Nonadherence with antidepres-
sant treatment has been estimated to range from 20.0 to 38.2% 
of patients [50], and has been associated with side effects and poor 
patient-physician communication [51]. When it has been established 
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that treatment resistance is due to failure of efficacy of at least two 
different antidepressants, then a specific treatment for TRD can 
be considered.
Few evidence-based therapies for TRD exist. The only therapy 
with current FDA approval is VNS. In November 2007, approxi-
mately 3000 VNS devices had been implanted for TRD world-
wide [52], suggesting that VNS is only used in a very small percent-
age of cases. For the great majority of patients psychotherapy and 
pharmacotherapy will be the predominant approaches.
Augmentation of antidepressants using atypical antipsychotics 
is a second- or third-line treatment for depression, used when 
patients have failed to respond or only partially responded to anti-
depressant monotherapy. Treatment options are derived from a 
consideration of factors including flexibility in dosing of fixed and 
nonfixed combinations, real or perceived differences in efficacy 
of different treatment strategies and different tolerability profiles 
of the different treatment options. Choice of agents can be made 
on a case-by-case basis taking into account an individual patient’s 
symptoms, history of response to previous medications, patient’s 
preference and side-effect profile.
Left untreated, TRD may develop into a chronic, debilitat-
ing illness with reduced quality of life and functional outcomes. 
More commonly, TRD is aggressively treated and associated 
with greater rates of hospitalization, greater medication use and 
a greater likelihood of receiving electroconvulsive therapy [53]. 
Pharmacotherapies, including augmentation and combination 
strategies, will continue to be the first line of treatment for TRD. 
Treatment with atypical/antidepressant combinations in general 
and OFC specifically are one of the options available. 
Five-year view
A combination of the impacts of chronicity and individual biol-
ogy may underpin TRD. The allostatic stress model supports a 
mechanism whereby there is a cumulative effect of multiple epi-
sodes, stressors and exogenous factors such as substance use [54]. 
A longer duration of chronic depression has been associated with 
reduced volumes in specific brain gray matter areas, such as the 
hippocampus [55], which may suggest a neurotoxic process possi-
bly mediated via mechanisms including cortisone, oxidative stress 
and cytokines [56–58]. Other factors, such as personality, social 
support, lifestyle and adverse life events influence the development 
of treatment resistance.
The mechanism by which olanzapine augments the antidepres-
sant efficacy of fluoxetine is still to be clarified. The role of the 
5-HT
2A
 receptor has been suggested to be of particular impor-
tance; however, further work is required. Increased dopamine 
has been associated with pleasure, reward and motivation [59], 
and increased dopamine and norepinephrine seen in the cortex 
of rats receiving olanzapine augmentation may also be a factor in 
its efficacy [31]. It is not known whether the olanzapine binding 
to dopaminergic, adrenergic, histaminic and muscarinic receptors 
contributes to its efficacy as an augmenting agent and this will 
need to be investigated. Indeed, much of our understanding of 
pathophysiology has been reverse engineered from understanding 
the mechanisms of useful agents.
There is no head-to-head clinical trial data for atypical anti-
psychotics as augmenting agents, or of atypical augmentation com-
pared with other augmentation strategies. SSRIs appear to have 
equivalent efficacy for the long-term management of MDD [60]. 
By contrast, as atypical agents differ substantially in their recep-
tor profiles, the precise mechanisms responsible for the efficacy of 
atypicals in depression remain to be defined. Class effects cannot 
be assumed and data on specific agents are needed. The prospects 
for treating TRD with combinations of atypical antipsychotics 
with antidepressants need to be balanced against the increased 
risk of adverse events associated with these combinations. 
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Key issues
Treatment-resistant depression (TRD) is a debilitating illness.• 
Efficacy data from clinical trials of TRD are limited.• 
Clinical trial data for atypical/antidepressant combinations • 
including the olanzapine/fluoxetine combination (OFC) suggest 
some efficacy and tolerability in accordance with the known 
profile of the individual agents.
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